← Back to Search

Thiazolidinedione

Prostate cancer on ADT receiving pioglitazone for Prostate Cancer

Phase 3

Waitlist Available

Led By Paresh Dandona, MD, PhD

Research Sponsored by State University of New York at Buffalo

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 weeks

Awards & highlights

Study Summary

This trial is testing if a diabetes drug can help reduce insulin resistance in men with prostate cancer who are taking ADT.

Eligible Conditions

Prostate Cancer
Insulin Resistance
Type 2 Diabetes
Low Testosterone

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

HOMA-IR

Secondary outcome measures

AKT-2

GLUT-4

IKK-β

+9 more

Trial Design

3Treatment groups

Active Control

Placebo Group

Group I: Prostate cancer on ADT receiving pioglitazoneActive Control1 Intervention

Subjects will receive a 12-week supply of pioglitazone 30 mg dose 1 tab daily

Group II: Prostate cancer not on ADTActive Control1 Intervention

No intervention will be done in this group

Group III: Prostate cancer on ADT receiving placeboPlacebo Group1 Intervention

Subjects will receive a 12 week supply of placebo pills containing cellulose

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Center for Advancing Translational Sciences (NCATS)NIH

320 Previous Clinical Trials

401,730 Total Patients Enrolled

1 Trials studying Prostate Cancer

100 Patients Enrolled for Prostate Cancer

State University of New York at BuffaloLead Sponsor

246 Previous Clinical Trials

49,488 Total Patients Enrolled

1 Trials studying Prostate Cancer

30 Patients Enrolled for Prostate Cancer

Paresh Dandona, MD, PhDPrincipal InvestigatorSUNY at Buffalo

3 Previous Clinical Trials

76 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any other ongoing clinical trials testing the effect of pioglitazone on Prostate cancer patients receiving ADT?

"At the moment, there are 32 different clinical trials studying the effects of pioglitazone on prostate cancer patients receiving ADT. 4 of those studies are currently in Phase 3. Most of the trials for Prostate cancer on ADT receiving pioglitazone are happening in Lausanne, Vaud, but there are a total of 70 locations running these trials."

Answered by AI

What conditions does pioglitazone commonly treat when given to patients with prostate cancer on ADT?

"Prostate cancer patients on ADT that take pioglitazone may find that their diabetes, diabetic neuralgia, and diet improve."

Answered by AI

Has the FDA given pioglitazone the okay to treat prostate cancer patients receiving ADT?

"Prostate cancer patients on ADT who receive pioglitazone are estimated to be at a 3 safety-wise because this is a Phase 3 trial."

Answered by AI

How many individuals are being enrolled in this research project?

"The clinicaltrials.gov website does show that this clinical trial is open and recruiting patients. This particular study was first made public on August 1st, 2021 and has since been updated on October 26th, 2022. Only 40 patients are needed for this trial, which is taking place at a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pioglitazone and Insulin Resistance in ADT

paresh Dandona 2021. "Pioglitazone and Insulin Resistance in ADT". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05098327.